NT
Intellia Therapeutics, Inc.
NTLA · NASDAQ
$12.21 -2.32% (-$0.29)
1M +1.58%
Market Cap $1.71B
P/E Ratio -
Div. Yield -
ROE 57.79%
Piotroski F-Score Weak
3/9Valuation
40 /100
Fair P/B 2.34x
P/S 28.67x
P/FFO N/A
Growth
49 /100
Stable Book val. growth 18.40%
Rev. growth 9.09%
FCF growth N/A
Profitability
0 /100
Weak Op. margin 711.66%
Gross margin 46.48%
FCF margin 783.30%
Quality
1 /100
Poor ROA 46.66%
ROIC 52.86%
Asset turnover 0.07x
Debt
100 /100
Low Current ratio 6.65x
Debt/Equity 0.10x
Debt/Assets N/A
Stability
33 /100
Unstable EPS volatility 12.29%
Beta 1.82x
Profitable years 0
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre NTLA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
John Leonard
Employees
377
Headquarters
Cambridge
Evenimente viitoare
05 NOV.
Earnings
Upcoming earnings report